Developing

Overlooked or Underutilized anti-cancer drugs

Developing

Overlooked or Underutilized anti-cancer drugs

Developing

Overlooked or Underutilized anti-cancer drugs

February 18, 2014: Update Pharma receives Orphan Drug Approval

Mission

Update Pharma, Inc. is a clinical-stage small molecule company focused on developing overlooked or underutilized anti-cancer drugs. Our lead compound, UPI-928 is a compound originally developed more than 20 years ago. It has demonstrated clinical efficacy and acceptable tolerability in Acute Myeloid Leukemia (AML) and other oncology indications including refractory breast cancer, myeloma, and ovarian cancer.

History of UPI-928

UPI-928 was originally developed by a major international pharmaceutical company. From the early 1980's through the early 1990's over 40 phase I, II and III clinical trials were conducted with this agent around the world, including extensive study at the National Cancer Institute (NCI).

About twenty years ago it was approved in Europe. However, following the sale of the parent company and the subsequent sale of the purchasing company, the drug has never been marketed, despite having been shown to possess a tolerable safety profile and therapeutic efficacy in various cancer indications. UPI-928 is an unusual agent with many mechanisms of action, including direct cytotoxic actions, immunologic mechanisms, and genomic effects.

UPI-928 is an agent that has been extensively tested in the clinic and approved for human use, albeit not marketed. Because of its multiple mechanisms of action, this unusual agent may have a role in combinatorial regimens that bridge the use of immune and cytotoxic agents. It needs to be assessed in the light of contemporary science, which is what we are doing at Update Pharma, Inc.